<DOC>
	<DOCNO>NCT01133873</DOCNO>
	<brief_summary>The purpose study determine daily maximum tolerate dose propoxyphene napsylate healthy subject .</brief_summary>
	<brief_title>Multiple-Ascending-Dose Study Evaluate Safety Propoxyphene Napsylate In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dextropropoxyphene</mesh_term>
	<criteria>Body mass index ≥ 18 ≤ 30 ( kg/m2 ) Medically healthy normal screen result , case result abnormal ; abnormal result clinically insignificant ( eg , medical history , physical examination , neurological assessment , vital sign , oxygen saturation , laboratory profile ) 12lead ECGs ( calculation electrocardiograph ) clinically significant finding Vital sign within normal range No tobacco/nicotinecontaining product use minimum 6 month If female , must able adhere acceptable method contraception postmenopausal surgically sterile History presence significant cardiovascular , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological disease History presence degree chronic obstructive pulmonary disease History suicidal ideation depression require professional intervention include counsel antidepressant medication Any history drug alcohol abuse Positive drug ( urine ) /alcohol ( breath ) test screen checkin Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) History hypersensitivity allergy propoxyphene opioid compound , naloxone , naltrexone , palonosetron ( Aloxi® ) , glycerin , senna , bisacodyl ( Dulcolax® ) Use prescription medication ( exception hormonal contraceptive female ) within 2 week enrollment Use overthecounter medication , include herbal product , within 1 week enrollment Use drug know significantly inhibit induce liver enzyme involve drug metabolism [ CYP P450 ] ) within 30 day enrollment Blood donation significant blood loss within 30 day enrollment Plasma donation within 7 day enrollment Participation another clinical trial within 30 day enrollment Females pregnant lactate Any condition prior therapy , , opinion PI , would make subject unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>